# Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients

> **NCT03006419** · PHASE4 · COMPLETED · sponsor: **Coordinación de Investigación en Salud, Mexico** · enrollment: 100 (actual)

## Conditions studied

- Kidney Transplant Rejection
- Kidney Transplant; Complications

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Thymoglobulin

## Key facts

- **NCT ID:** NCT03006419
- **Lead sponsor:** Coordinación de Investigación en Salud, Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-01
- **Primary completion:** 2019-07-30
- **Final completion:** 2019-07-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03006419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03006419, "Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03006419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*